:format(jpeg):focal(2715x1275:2725x1265)/cloudfront-us-east-1.images.arcpublishing.com/gfrmedia/SGRSZPTHDBHUZPVROYSIEUIM5E.jpg)
Barcelona — A blood test allows diagnosing the disease Alzheimer’s with an accuracy of around 95%, according to the results of a study published by the journal ‘JAMA Neurology’, in which researchers from the Hospital de Sant Pau, in Barcelona, Spain, participated.
This investigation, aimed at finding biomarkers in the blood that allow the diagnosis to be made in a less invasive wayconfirms that the Phosphorylated TAU protein 217 (p-tau217) shows high accuracy in identifying pathologyaccording to the Catalan hospital.
A few years ago, the only possibility of detecting this neurodegenerative disease was the ‘post-mortem’ study of the brain, until biomarkers were found that allow it to be identified by analyzing the cerebrospinal fluid. This study demonstrates that p-tau217 offers comparable accuracy to cerebrospinal fluid biomarkers and is particularly effective in detecting longitudinal changes, even in preclinical stages of the disease.
The researcher of the Neurobiology of Dementia Group at the Sant Pau Research Institute and responsible for the biomarker platform of the Memory Unit of the same hospital, Dr. Daniel Alcolea, assures that “of all the biomarkers that are currently being studied, this It is the one that has given the best results.” Besides, This new technique could reduce the need for additional testing needed to confirm the diagnosis by 80%.
In this sense, the researcher and director of the Neurology Service of the same hospital, Dr. Alberto Lleo, assures that “Implementation of this type of test could significantly improve clinical evaluation and clinical trial recruitment, as well as facilitate patient management and provide timely access to disease-modifying therapies.”
The study is based on samples of 786 patients with an average age of 66.3 years analyzed in Sweden. The researchers analyzed data from three observational cohorts: the Translational Biomarkers in Aging and Dementia (TRIAD), from Canada; the Wisconsin Registry for Alzheimer’s Prevention (WRAP), from the United States, and the Sant Pau Initiative on Neurodegeneration (SPIN), from Barcelona.
